Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01328093 · ClinicalTrials.gov registry record · Phase 3
A Comparison Study of LY2140023 and Aripiprazole in Schizophrenia Patients
A Phase 3 study, sponsored by Denovo Biopharma.
- Terminated
- Registry status
- Phase 3
- Development phase
- 678
- Enrollment target
NCT01328093: Clinical Trial Phase 3 study, sponsored by Denovo Biopharma.
NCT01328093 is a Phase 3 study that was terminated before completion, run by Denovo Biopharma. The registered enrollment target is 678 participants, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (12% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01328093, a Phase 3 study, was terminated before completion, sponsored by Denovo Biopharma.
- TERMINATED
- Registry status
- Phase 3
- Development phase
- 678 participants
- Enrollment target
Study Summary
The purpose of this study is to determine whether weight gain will be significantly less in LY2140023 than aripiprazole in patients with schizophrenia.
Primary Outcome
Mixed model repeated measures (MMRM) analysis was used to calculate Least Squares (LS) mean and standard error. LS mean values were adjusted for baseline, treatment, gender, pooled investigator, visit, prior olanzapine use, treatment-by-visit interaction and baseline-by-visit interaction.
Interventions
- DRUG Aripiprazole
- DRUG LY2140023
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 678 participants |
| Start Date | 2011-04 |
| Est. Completion | 2012-10 |
| Phase | Phase 3 |
Why NCT01328093 stopped before completion
NCT01328093 is an interventional study that assigns participants to a tested intervention. The registered 678 participants enrollment target is mid-sized for trials with a published cap, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (12% lower).
The record links to 0 conditions, and to 2 interventions - of which Aripiprazole is the first listed.
NCT01328093 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01328093 about?
NCT01328093 is a clinical study titled "A Comparison Study of LY2140023 and Aripiprazole in Schizophrenia Patients". The purpose of this study is to determine whether weight gain will be significantly less in LY2140023 than aripiprazole in patients with schizophrenia.
What is the current status of trial NCT01328093?
This trial is currently terminated. It is a Phase 3 study. The enrollment target is 678 participants. The study started on 2011-04. Estimated completion is 2012-10.
What interventions are being tested in trial NCT01328093?
The interventions under investigation include: Aripiprazole (DRUG), LY2140023 (DRUG).
Who is sponsoring clinical trial NCT01328093?
This trial is sponsored by Denovo Biopharma, which has 10 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT01328093's enrollment target sits among peer trials
678 536th of 2000 higher than 1,464 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05372484 · 678 participants · NA
Rice Technologies for Cervical Cancer Screening and Diagnosis
- NCT06436924 · 678 participants
Safety and Efficacy of Workflows of High Volume Single Operators in a LAAO Device Implant Procedural Day
- NCT03501706 · 680 participants · NA
An Assessment of Cognitive Improvement Training Among Mid-life Individuals
- NCT05626452 · 680 participants · NA
PrEP Optimization Among Women to Enhance Retention and Uptake
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia